Cyclacel Pharmaceuticals Bolsa (NASDAQ: CYCC)

Últimas noticias sobre Cyclacel Pharmaceuticals (NASDAQ:CYCC) Bolsa

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

<h3>Gainers</h3>
<ul>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares increased by 142.8% to $1.07 during Friday's regular session. The market value of their outstanding shares is at $3.0 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares moved upwards by 49.28% to $2.06. The market value of their outstanding shares is at $351.5 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock rose 39.74% to $0.92. The company's market cap stands at $3.6 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock rose 30.56% to $0.63. The company's market cap stands at $13.1 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock rose 30.46% to $1.32. The market value of their outstanding shares is at $2.6 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) stock rose 27.86% to $1.15. The market value of their outstanding shares is at $29.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares fell 31.9% to $0.48 during Friday's regular session. The company's market cap stands at $16.8 million. </li>
<li>Orgenesis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>) shares declined by 28.05% to $2.33. The market value of their outstanding shares is at $11.1 million. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) stock decreased by 16.1% to $0.78. The market value of their outstanding shares is at $5.1 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) stock declined by 12.7% to $2.27. The company's market cap stands at $17.8 million. </li>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares decreased by 9.04% to $0.7. The market value of their outstanding shares is at $4.0 million. </li>
<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares fell 8.84% to $1.96. The company's market cap stands at $7.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BFRG

CHRO

CMAX

CTCX

CYCC

MHUA

MTEM

NKGN

ORGS

QNRX

TVGN

VTAK

12 Health Care Stocks Moving In Friday's Intraday Session

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", )))), a biopharmaceutical company developing innovative cancer medicines, today announced that initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101 clinical study of fadraciclib as a single agent will be presented as a poster at the 2024 AACR-NCI-EORTC 36th Symposium on Molecular Targets and Cancer Therapeutics ("Triple Meeting"), to be held in Barcelona, Spain (October 23-25, 2024). The patients were enrolled in the biomarker-enriched, Cohort 8 of the proof of concept study and were preselected for CDKN2A and/or CDKN2B abnormalities.
Details of the presentation are listed below:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td><a href="https://cm.eortc.org/cmPortal/Searchable/ena2024/config/Normal#!sessiondetails/0000110740_0">Fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma with CDKN2A and/or CDKN2B genetic alterations</a></td>
</tr>
<tr>
<td>Abstract Number:</td>
<td>59</td>
</tr>
<tr>
<td>Session:</td>
<td>Molecular Targeted Agents</td>
</tr>
<tr>
<td>Date/Time:</td>
<td>12:00 p.m. – 7:00 p.m. CEST on Wednesday, October 23, 2024</td>
</tr>
</tbody>
</table>
</figure>

Biotech

News

General

CYCCP

Cyclacel Pharmaceuticals To Present New Clinical Data From Phase 2 Study Of Oral Fadraciclib At The 2024 EORTC-NCI-AACR Symposium

Cyclacel Pharmaceuticals Completes Enrollment Of 12 Patients In Cohort 8 Of Phase 2 Study For Fadraciclib In Advanced Solid Tumors And Lymphoma; Safety And Efficacy Data To Be Presented At Upcoming Oncology Conference

A downtrend has been apparent in Cyclacel Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cycc#NASDAQ">CYCC</a>) lately. While the stock has lost 13.8% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.
The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the stock. On the fundamental side, strong agreement among Wall Street analysts in raising earnings estimates for this company enhances its prospects of a trend reversal.
<img alt="1-month candlestick chart for CYCC" class="chart" src="https://staticx-tuner.zacks.com/images/articles/charts/yseop/550/CYCC_Hammer.jpeg" style="height:auto; width:100%" title="" />
<h2>Understanding Hammer Chart and the Technique to Trade It</h2>
This is one of the popular price patterns in candlestick charting. A minor difference between the opening and closing prices forms a small candle body, and a higher difference between the low of the day and the open or close forms a long lower wick (or vertical line). The length of the lower wick being at least twice the length of the real body, the candle resembles a &#39;hammer.&#39;
In simple terms, during a downtrend, with bears having absolute control, a stock usually opens lower compared to the previous day&#39;s close, and again closes lower. On the day the hammer pattern is formed, maintaining the downtrend, the stock makes a new low. However, after eventually finding support at the low of the day, some amount of buying interest emerges, pushing the stock up to close the session near or slightly above its opening price.
When it occurs at the bottom of a downtrend, this pattern signals that the bears might have lost control over the price. And, the success of bulls in stopping the price from falling further indicates a potential trend reversal.
Hammer candles can occur on any timeframe -- such as one-minute, daily, weekly -- and are utilized by both short-term as well as long-term investors.
Like every technical indicator, the hammer chart pattern has its limitations. Particularly, as the strength of a hammer depends on its placement on the chart, it should always be used in conjunction with other bullish indicators.
<h2>Here&#39;s What Makes the Trend Reversal More Likely for CYCC</h2>
An upward trend in earnings estimate revisions that CYCC has been witnessing lately can certainly be considered a bullish indicator on the fundamental side. That&#39;s because empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
Over the last 30 days, the consensus EPS estimate for the current year has increased 53.6%. What it means is that the sell-side analysts covering CYCC are majorly in agreement that the company will report better earnings than they predicted earlier.
If this is not enough, you should note that CYCC currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. And stocks carrying a Zacks Rank #1 or 2 usually outperform the market.
Moreover, a Zacks Rank of 2 for Cyclacel Pharmaceuticals is a more conclusive indication of a potential trend reversal, as the Zacks Rank has proven to be an excellent timing indicator that helps investors identify precisely when a company&#39;s prospects are beginning to improve.
<a href="https://www.zacks.com/stock/news/2330350/cyclacel-pharmaceuticals-cycc-may-find-a-bottom-soon-here-s-why-you-should-buy-the-stock-now?cid=CS-BENZ-FT-tale_of_the_tape|hammer_chart_pattern_(ta)-2330350">To read this article on Zacks.com click here.</a>

Earnings

Mid Cap

Penny Stocks

Technicals

Markets

Analyst Ratings

Trading Ideas

Cyclacel Pharmaceuticals May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Cyclacel Pharmaceuticals Files Appeal To Nasdaq Staff Delisting Letter

Shares of Zhibao Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAO#NASDAQ">ZBAO</a>) rose sharply in today's pre-market trading after the company announced that it has won a tender to provide high-end medical third party administration services to the People&#8217;s<a href="https://www.benzinga.com/quote/ZBAO/news"> Insurance Company of China Limited.</a>
Zhibao Technology shares jumped 18.8% to $3.99 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) gained 129.4% to $0.7599 in pre-market trading. Sify becomes first in India to achieve NVIDIA DGX-ready data center certification for liquid cooling to enable breakthrough AI performance.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) rose 48.1% to $0.6040 in today's pre-market trading after the company announced a $10 million loan through a Facility Agreement with Hanmi Pharmaceutical Co.</li>
<li>Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) gained 25.8% to $0.1549 in pre-market trading after declining over 5% on Friday.</li>
<li>Perfect Moment Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PMNT#NYSE">PMNT</a>) gained 25.2% to $1.29 in pre-market trading.</li>
<li>Cyclacel Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) gained 21.7% to $1.28 in pre-market trading.</li>
<li>Polar Power Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POLA#NASDAQ">POLA</a>) gained 18.8% to $0.47 in the pre-market trading session. Polar Power, last month, posted a profit for the second quarter.</li>
<li>QuantaSing Group Ltd- ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) gained 13.2% to $1.97 in pre-market trading.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) rose 11.5% to $6.01 in pre-market trading.</li>
<li>Autozi Internet Technology (Global) Ltd.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZI#NASDAQ">AZI</a>) gained 5% to $3.15 in pre-market trading amid post-IPO volatility.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Bluejay Diagnostics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) fell 13.3% to $0.16 in pre-market trading after declining around 6% on Friday.</li>
<li>Focus Universal Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCUV#NASDAQ">FCUV</a>) shares fell 13.1% to $0.2338 in pre-market trading. Focus Universal shares jumped over 41% on Friday after the company in a Form4 filing disclosed that CEO Desheng Wang bought 302,100 shares of stock at an average price of $0.18 per share.</li>
<li>Staffing 360 Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) shares declined 12.1% to $2.05 in pre-market trading.</li>
<li>Graphex Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRFX#NYSE">GRFX</a>) fell 12% to $0.21 in pre-market trading after surging 13% on Friday.</li>
<li>ShiftPixy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIXY#NASDAQ">PIXY</a>) shares fell 11.8% to $1.04 in pre-market trading. ShiftPixy recently announced the pricing of $2.5 million offering.</li>
<li>Agape ATP Corporation  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares declined 11.4% to $2.26 in pre-market trading after jumping 60% on Friday.</li>
<li>Autonomix Medical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares fell 10.9% to $0.60 in pre-market trading after jumping 14% on Friday.</li>
<li>Theriva Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#NASDAQ">TOVX</a>) fell 10% to $5.31 in today's pre-market trading after gaining over 25% on Friday.</li>
<li>United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) shares dipped 5.8% to $35.70 in pre-market trading. Vice President Kamala Harris has expressed her support for American ownership of United States Steel, amidst ongoing foreign acquisition attempts.</li>
<li>Diversified Energy Company PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEC#NYSE">DEC</a>) declined 5.6% to $11.54 in pre-market trading. Keybanc analyst Tim Rezvan, last week, initiated coverage on Diversified Energy with an Overweight rating and announced a price target of $18.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40677064/this-analyst-with-87-accuracy-rate-sees-over-24-upside-in-nvidia-here-are-5-stock-picks-for-last-wee">This Analyst With 87% Accuracy Rate Sees Over 24% Upside In Nvidia &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Pre-Market Outlook

AMIX

APTO

ATPC

BJDX

FCUV

GRFX

PIXY

PMNT

POLA

SHLS

SIFY

STAF

TOVX

ZBAO

Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket

Cyclacel Receives Grant Of European Patent EP4013503 Titled "Crystalline Forms Of Pyrimidino Diazepine Derivative For The Treatment Of Tumors"

Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(1.44) by 50 percent. The company reported quarterly sales of $4.00 thousand which missed the analyst consensus estimate of $30.00 thousand by 86.67 percent. This is a 98.93 percent decrease over sales of $373.00 thousand the same period last year.

Earnings Beats

Earnings Misses

Cyclacel Pharmaceuticals Q2 2024 GAAP EPS $(0.72) Beats $(1.44) Estimate, Sales $4.00K Miss $30.00K Estimate

Cyclacel Pharmaceuticals to Receive European Patent Grant for Novel Pharmaceutical Compositions of Plogosertib; Patent Provides Exclusivity Until August 2040; Applications in Other Jurisdictions Pending

<h3>Gainers</h3>
<ul>
<li>Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) shares rose 24.5% to $36.0 during Wednesday's pre-market session. The company's market cap stands at $3.4 billion. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares moved upwards by 18.43% to $5.91. The market value of their outstanding shares is at $196.1 million. </li>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares increased by 15.84% to $0.95. The company's market cap stands at $6.0 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares increased by 15.74% to $1.25. The market value of their outstanding shares is at $3.3 million. </li>
<li>Oramed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORMP#NASDAQ">ORMP</a>) stock moved upwards by 14.49% to $2.37. The market value of their outstanding shares is at $96.2 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock rose 12.72% to $3.1. The market value of their outstanding shares is at $3.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ThermoGenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) shares decreased by 40.5% to $0.33 during Wednesday's pre-market session. The company's market cap stands at $2.6 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares fell 11.86% to $0.24. The market value of their outstanding shares is at $15.2 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares decreased by 10.94% to $0.57. The market value of their outstanding shares is at $35.4 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares decreased by 8.28% to $0.8. The company's market cap stands at $132.8 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares decreased by 8.11% to $1.7. The market value of their outstanding shares is at $2.4 million. </li>
<li>Bright Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) stock fell 7.91% to $0.28. The market value of their outstanding shares is at $53.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGXX

CLDI

LGVN

MOLN

ORMP

STRM

TCON

THMO

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock rose 131.0% to $1.43 during Thursday's after-market session. The market value of their outstanding shares is at $9.0 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares increased by 8.58% to $2.15. The market value of their outstanding shares is at $3.1 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock moved upwards by 8.27% to $0.59. The market value of their outstanding shares is at $6.0 million. </li>
<li>Kiora Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPRX#NASDAQ">KPRX</a>) shares rose 5.0% to $0.45. The market value of their outstanding shares is at $11.9 million. </li>
<li>Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) shares moved upwards by 4.94% to $6.79. The market value of their outstanding shares is at $325.2 million. </li>
<li>Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) shares rose 4.69% to $1.56. The company's market cap stands at $64.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) stock fell 61.9% to $4.3 during Thursday's after-market session. The company's market cap stands at $154.5 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock fell 13.49% to $0.77. The company's market cap stands at $127.9 million. </li>
<li>Bright Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) stock fell 8.55% to $0.32. The market value of their outstanding shares is at $61.0 million. </li>
<li>Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) shares decreased by 6.89% to $2.3. The market value of their outstanding shares is at $162.0 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock fell 6.84% to $0.51. The company's market cap stands at $2.6 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares decreased by 6.46% to $0.17. The market value of their outstanding shares is at $3.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

APDN

BMEA

GUTS

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

ONCO

RLYB

TRVI

VERO

12 Health Care Stocks Moving In Thursday's After-Market Session

&nbsp;- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific&nbsp;mechanism of action -
BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, "Cyclacel" or the "Company")))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced a presentation by independent investigators of preclinical data demonstrating therapeutic potential of fadraciclib, the Company's cyclin-dependent kinase (CDK) 2/9 inhibitor, as a novel treatment for metastatic colorectal cancer (CRC). The data show that fadraciclib substantially inhibited growth, triggered apoptosis, and induced anaphase catastrophe in CRC patient-derived organoids (PDOs) and xenografts (PDX). The data were presented at a <a href="https://www.globenewswire.com/Tracker?data=DOtUFRdBtrXaK5j-6KOi9X0-hbH0ydRIk4A7NebSXHpepFg5T43Sm2lqcEZaB9MhN78G8X5rZiZF-CqNFKGoPEFhXLhi_bYvWpZ6wbWbacpHcPosIYMjFCZljBkcsdAVTp8kDpjWpncZht2KspSMWrYlEj0jyel-Ba42fDMofB4=">poster</a> at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago, IL.

Cyclacel's Fadraciclib Reports Efficacy In Patient-Derived Colorectal Cancer Models At The 2024 ASCO Annual Meeting

- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma - &nbsp;
BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", )))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data from the CYC065-101 study of fadraciclib as oral monotherapy was presented at a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago, IL. See link to poster <a href="https://www.globenewswire.com/Tracker?data=rfrkrSM078zh7iszbcFVULyR3lG5tiG0EXp4_KyOnMETwe9v1h1WCv1dTWVsjKgWU9HxZYK4N6yf0oZyJChLR7VVpi5R-SNfqaVYarS-TGnLBad1oxxJRFyzfzZCa0ivJ2cO8emlzfrFzTo29-HMsw==">here</a>.

Cyclacel Pharmaceuticals To Present Clinical Data At 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib's Potential As A Precision Medicine For Cancer

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares rose 50.5% to $0.32 during Friday's after-market session. The market value of their outstanding shares is at $5.0 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares increased by 9.75% to $2.25. The market value of their outstanding shares is at $3.2 million. </li>
<li>Lucy Scientific Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) stock moved upwards by 6.89% to $0.93. The market value of their outstanding shares is at $1.6 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares increased by 6.4% to $1.33. The company's market cap stands at $5.6 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares rose 5.4% to $1.17. The market value of their outstanding shares is at $83.3 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares moved upwards by 4.98% to $0.56. The market value of their outstanding shares is at $39.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock fell 24.4% to $1.21 during Friday's after-market session. The market value of their outstanding shares is at $49.0 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) stock fell 14.04% to $0.84. The market value of their outstanding shares is at $14.7 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares decreased by 9.1% to $1.8. The company's market cap stands at $2.1 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock fell 7.75% to $0.29. The market value of their outstanding shares is at $3.5 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares decreased by 7.4% to $2.13. The company's market cap stands at $50.8 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock decreased by 7.18% to $0.29. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRS

ADIL

BCLI

DHAI

ISPC

LSDI

LUCY

ONMD

STSS

SXTP

WORX

12 Health Care Stocks Moving In Friday's After-Market Session

Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) reported quarterly losses of $(2.27) per share which beat the analyst consensus estimate of $(4.74) by 52.11 percent. This is a 67.8 percent increase over losses of $(7.05) per share from the same period last year. The company reported $29.00 thousand in sales this quarter.

Cyclacel Pharmaceuticals Q1 EPS $(2.27) Beats $(4.74) Estimate, Sales $29.00K

Shares of Akoustis Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTS#NASDAQ">AKTS</a>) fell sharply in today's session following <a href="https://www.benzinga.com/quote/AKTS/earnings">weak quarterly results</a>.
Akoustis Technologies posted adjusted loss of 14 cents per share, versus market expectations for a loss of 12 cents per share. Sales came in at $7.510 million missing estimates of $8.553 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Akoustis Technologies shares dipped 17.7% to $0.4671 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares jumped 81.6% to $31.70 amid possible retail investor interest following a social media post by Roaring Kitty.</li>
<li>KOSS Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOSS#NASDAQ">KOSS</a>) rose 49.4% to $4.73 trading after declining around 10% on Friday. Koss posted a wider quarterly loss last week.</li>
<li>CareCloud, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) gained 33.2% to $1.68 after the company announced it retained an investment bank to examine and evaluate the terms of its Series A Preferred Stock and to make recommendations to the board that may be beneficial to the company and its shareholders.</li>
<li>AC Immune SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIU#NASDAQ">ACIU</a>) gained 31% to $3.02 after the company reported first-quarter financial results. Also, the company announced it signed an exclusive option and license agreement with Takeda for active immunotherapy targeting amyloid beta for Alzheimer&#8217;s disease.</li>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) climbed 28.9% to $4.77.</li>
<li>Cazoo Group Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CZOO#NYSE">CZOO</a>) rose 28.2% to $7.55.</li>
<li>Tevogen Bio Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) climbed 27% to $1.25 after the company announced up to $50 million in financing to further advance operational objectives.</li>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) gained 24.2% to $0.3849.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) gained 21% to $3.48.</li>
<li>The Children&#8217;s Place, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>) rose 21.1% to $13.30.</li>
<li>Beyond, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) climbed 20% to $20.23. Beyond Director Joseph J Tabacco Jr acquired a total of 12,400 shares  an average price of $16.01.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) gained 16.4% to $10.01. Recursion announced completion of NVIDIA-Powered BioHive-2 AI Pharma Supercomputer.</li>
<li>iRobot Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) rose 16.4% to $13.06. iRobot, last week, reported better-than-expected first-quarter financial results.</li>
<li>SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) gained 15.7% to $2.66.</li>
<li>AMC Networks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMCX#NASDAQ">AMCX</a>) rose 14% to $15.17. AMC Networks, last week, reported a fiscal first-quarter 2024 revenue decline of 16.9% year over year to $596.46 million, missing the analyst consensus estimate of $602.60 million.</li>
<li>Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) gained 13.7% to $3.0250.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) gained 13.6% to $0.1659. Nauticus Robotics is expected to release its first quarter financial and operating results after the closing bell on May 13.</li>
<li>Newegg Commerce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) climbed 13.3% to $0.9495. Newegg received Nasdaq notification regarding minimum bid requirements.</li>
<li>Squarespace, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQSP#NYSE">SQSP</a>) gained 13.1% to $43.21. Squarespace announced today that it has agreed to go private in a deal with global private equity firm Permira, in a transaction valued at over $6.6 billion on an equity value basis and approximately $6.9 billion on an enterprise value basis.</li>
<li>Spirit Airlines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) rose 12.2% to $4.2650.</li>
<li>Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) gained 12.1% to $9.95. Novavax shares jumpd 99% on Friday after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and develop COVID-influenza combination vaccines.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) rose 10.9% to $59.37.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) gained 10.8% to $5.62. Nio's CEO William Li has reportedly purchased a vehicle from its rival EV maker XPeng.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) gained 8.6% to $2.4636. Cyclacel Pharmaceuticals is expected to announce first quarter 2024 financial results on Tuesday, May 14.</li>
<li>Groupon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) shares rose 5% to $13.60. Groupon shares jumped around 24% on Friday after the company reported better-than-expected first-quarter results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Barnes &amp; Noble Education, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNED#NYSE">BNED</a>) shares fell 41.6% to $0.1699 after declining 7% on Friday. Barnes &amp; Noble Education, during April, announced a short-term shareholder rights plan and a new equity investment.</li>
<li>Seritage Growth Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRG#NYSE">SRG</a>) fell 35% to $6.05 after the company reported first-quarter financial results.</li>
<li>Amprius Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NASDAQ">AMPX</a>) fell 31.5% to $1.3488 after the company announced a temporary offer allowing public and private warrants to be exercised at a reduced price.</li>
<li>Heart Test Laboratories, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) declined 19.3% to $0.0710. On May 9, the company received staff determination from the Nasdaq to delist the company's securities from Nasdaq Capital Market.</li>
<li>Dingdong (Cayman) Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDL#NYSE">DDL</a>) dipped 16.6% to $1.7996 following first-quarter financial results.</li>
<li>The Singing Machine Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MICS#NASDAQ">MICS</a>) declined 15.3% to $0.8133.</li>
<li>Antelope Enterprise Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) shares dipped 14.2% to $1.6383. Antelope Enterprise, last week, announced second half and full year 2023 financial results.</li>
<li>Healthcare Triangle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) fell 13.4% to $0.8699.</li>
<li>Fortrea Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) shares declined 12.6% to $28.85 after the company reported soft first-quarter results and cut its revenue outlook.</li>
<li>NL Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NL#NYSE">NL</a>) dipped 11.5% to $6.97.</li>
<li>Power REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PW#NYSE">PW</a>) shares fell 11.1% to $0.61 after jumping around 58% on Friday.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares fell 10.4% to $1.0584. Aethlon Medical, on Friday, announced results from an in vitro binding study of its Hemopurifier in removing extracellular vesicles from plasma.</li>
<li>JanOne Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAN#NASDAQ">JAN</a>) fell 9% to $3.6692 after the company announced plans to acquire ALT 5 Sigma Inc.</li>
<li>CompX International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIX#NYSE">CIX</a>) dipped 8.1% to $22.94.</li>
<li>MKS Instruments, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) fell 6.5% to $122.00 as the company announced a proposed private offering of $1 billion of convertible senior notes</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/05/38789351/taiwan-semiconductor-applied-materials-and-more-on-cnbcs-final-trades">Taiwan Semiconductor, Applied Materials And More On CNBC&#8217;s &#8216;Final Trades</a>&#8216;

Intraday Update

ACIU

AEHL

AKTS

AMCX

AMPX

BNED

BYON

CCLD

CZOO

FTRE

GRPN

HCTI

HSCS

IRBT

KITT

KOSS

LCID

MICS

MKSI

NEGG

NVAX

NWTN

PLCE

RDDT

RXRX

SAVE

SPWR

SQSP

TWOU

Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of JanOne Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAN#NASDAQ">JAN</a>) rose sharply in today's pre-market trading after the company announced plans to <a href="https://www.benzinga.com/quote/JAN/news">acquire ALT 5 Sigma Inc</a>.
The deal is projected to close in the week of May 13th.
JanOne shares jumped 18.6% to $4.78 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Tevogen Bio Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) gained 74.7% to $1.72 in pre-market trading after the company announced up to $50 million in financing to further advance operational objectives.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) gained 31.3% to $0.1928 in pre-market trading. Nauticus Robotics is expected to release its first quarter financial and operating results after the closing bell on May 13.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares gained 16.7% to $20.40 in pre-market trading following a 3% decline on Friday.</li>
<li>KOSS Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOSS#NASDAQ">KOSS</a>) rose 15.4% to $3.69 in today's pre-market trading after declining around 10% on Friday. Koss posted a wider quarterly loss last week.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) gained 15% to $2.61 in pre-market trading. Cyclacel Pharmaceuticals is expected to announce first quarter 2024 financial results on Tuesday, May 14.</li>
<li>Assure Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) shares gained 10.7% to $0.48 in pre-market trading after gaining 3% on Friday.</li>
<li>WaveDancer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAVD#NASDAQ">WAVD</a>) shares rose 9.2% to $3.34 in pre-market trading.</li>
<li>Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) gained 8.2% to $9.61 in pre-market trading. Novavax shares jumpd 99% on Friday after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and develop COVID-influenza combination vaccines.</li>
<li>Groupon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) shares rose 7.1% to $13.88 in pre-market trading. Groupon shares jumped around 24% on Friday after the company reported better-than-expected first-quarter results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Barnes &amp; Noble Education, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNED#NYSE">BNED</a>) shares dipped 33% to $0.1949 in pre-market trading after declining 7% on Friday. Barnes &amp; Noble Education, during April, announced a short-term shareholder rights plan and a new equity investment.</li>
<li>Seritage Growth Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRG#NYSE">SRG</a>) shares fell 23.6% to $7.12 pre-market trading after the company reported a loss for the first quarter.</li>
<li>Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) dipped 23.6% to $2.68 in pre-market trading after posting weak second-quarter results.</li>
<li>Caravelle International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CACO#NASDAQ">CACO</a>) shares fell 20.8% to $0.57 in pre-market trading after declining around 4% on Friday.</li>
<li>Portage Biotech Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares declined 20.7% to $0.20 in pre-market trading after falling 10% on Friday. The company, last month, announced that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares fell 18.6% to $0.96 in pre-market trading. Aethlon Medical, on Friday, announced results from an in vitro binding study of its Hemopurifier in removing extracellular vesicles from plasma.</li>
<li>Antelope Enterprise Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) shares dipped 16.2% to $1.60 in pre-market trading. Antelope Enterprise, last week, announced second half and full year 2023 financial results.</li>
<li>Visionary Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GV#NASDAQ">GV</a>) shares declined 12.7% to $0.3110 in pre-market trading after gaining around 10% on Friday.</li>
<li>Power REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PW#NYSE">PW</a>) shares fell 12.3% to $0.6011 in pre-market trading after jumping around 58% on Friday.</li>
<li>Vitesse Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTS#NYSE">VTS</a>) shares fell 10.2% to $21.64 in pre-market trading. Vitesse Energy, last week, posted downbeat quarterly earnings.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38781676/fear-greed-index-in-neutral-zone-dow-records-gains-for-8th-session">Fear &amp; Greed Index In &#8216;Neutral&#8217; Zone; Dow Records Gains For 8th Session</a>

CACO

IONM

PRTG

WAVD

Why JanOne Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket

Roth MKM analyst Jonathan Aschoff maintains Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) with a Buy and lowers the price target from $21 to $11.

Price Target

Roth MKM Maintains Buy on Cyclacel Pharmaceuticals, Lowers Price Target to $11

<h3>Gainers</h3>
<ul>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock increased by 154.6% to $4.15 during Wednesday's regular session. The market value of their outstanding shares is at $281.0 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares increased by 36.79% to $2.9. The market value of their outstanding shares is at $3.8 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares increased by 33.87% to $0.12. The company's market cap stands at $1.4 million. </li>
<li>Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) shares increased by 30.14% to $33.44. The market value of their outstanding shares is at $475.9 million. As per the news, the Q2 earnings report came out today. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares increased by 27.81% to $1.15. The market value of their outstanding shares is at $15.3 million. </li>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares rose 27.75% to $120.26. The company's market cap stands at $3.9 billion. As per the press release, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock declined by 36.9% to $9.79 during Wednesday's regular session. The market value of their outstanding shares is at $211.4 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares declined by 19.65% to $1.98. The market value of their outstanding shares is at $1.5 billion. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock fell 19.11% to $0.89. The company's market cap stands at $2.7 million. </li>
<li>BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) stock decreased by 18.38% to $0.39. The company's market cap stands at $21.5 million. </li>
<li>CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) stock fell 16.94% to $56.24. The market value of their outstanding shares is at $70.8 billion. The company's, Q1 earnings came out today. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) stock declined by 15.5% to $20.83. The company's market cap stands at $708.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

CTMX

CVRX

MNDR

PHGE

SRDX

TLRY

TMDX

YCBD

12 Health Care Stocks Moving In Wednesday's Intraday Session

Shares of Pinterest, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) rose sharply in today's pre-market trading following strong first-quarter earnings and upbeat <a href="https://www.benzinga.com/news/earnings/24/04/38534719/pinterests-ai-investments-are-paying-off-shares-surge-on-q1-earnings-beat">second-quarter guidance</a>.
Pinterest's first-quarter revenue increased nearly 23% year-over-year to $740 million, which beat the consensus estimate of $699.872 million, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. The company reported a loss of 4 cents per share, which beat analyst estimates for a loss of 9 cents per share.
Pinterest shares climbed 17.3% to $39.26 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Plutonian Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTN#NASDAQ">PLTN</a>) gained 68.9% to $15.00 in pre-market trading.</li>
<li>IM Cannabis Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) gained 40.7% to $1.21 in pre-market trading after jumping around 54% on Tuesday.</li>
<li>Predictive Oncology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) rose 31.4% to $1.88 in today's pre-market trading after the company announced a collaboration with FluGen for an intranasal flu vaccine.</li>
<li>Root, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) shares gained 27.2% to $88.61 in pre-market trading after the company reported better-than-expected first-quarter financial results.</li>
<li>Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) jumped 23.2% to $176.24 in pre-market trading after the company reported better-than-expected second-quarter financial results.</li>
<li>Lion Group Holding Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGHL#NASDAQ">LGHL</a>) shares gained 20.1% to $0.5850 in pre-market trading after the company reported a year-over-year increase in FY23 financial results.</li>
<li>Inari Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NARI#NASDAQ">NARI</a>) shares gained 12.5% to $42.01 in pre-market trading after the company reported better-than-expected first-quarter sales results and issued FY24 revenue guidance above estimates.</li>
<li>TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares rose 9.7% to $103.19 in pre-market trading after the company raised its 2024 guidance.</li>
<li>Lemonade, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) shares gained 9.4% to $18.85 in pre-market trading after the company reported better-than-expected first-quarter financial results and raised its FY24 revenue guidance above estimates.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>CVRx Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) fell 29.1% to $11.00 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
<li>Sobr Safe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares declined 14.6% to $0.26 in pre-market trading.</li>
<li>Leggett &amp; Platt, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEG#NYSE">LEG</a>) fell 12.8% to $15.75 in pre-market trading after the company posted weaker-than-expected results for its first quarter.</li>
<li>Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) shares fell 12.7% to $93.00 in pre-market trading after the company reported second-quarter financial results and issued third-quarter revenue guidance with the midpoint below estimates.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) shares fell 12.2% to $0.9999 in pre-market trading after dipping 36% on Tuesday.</li>
<li>Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) fell 12.1% to $77.79 pre-market trading following weaker-than-expected second-quarter earnings.</li>
<li>Splash Beverage Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBEV#NYSE">SBEV</a>) shares declined 11.6% to $0.2910 in pre-market trading after gaining around 12% on Tuesday.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares fell 10.8% to $1.89 in pre-market trading. Cyclacel Pharmaceuticals shares jumped around 56% on Tuesday after the company announced that it filed Form RW with the SEC, withdrawing its registration statement on Form S-1. The company also announced an $8 million private placement.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares declined 9% to $781.50 in pre-market trading following mixed third-quarter financial results.</li>
<li>InMed Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INM#NASDAQ">INM</a>) fell 7.1% to $0.25 pre-market trading.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38542047/amazon-pfizer-and-3-stocks-to-watch-heading-into-wednesday">Amazon, Pfizer And 3 Stocks To Watch Heading Into Wednesday</a>

CETX

IMCC

LGHL

LMND

NARI

PINS

PLTN

POAI

POWL

ROOT

SBEV

SBUX

SMCI

SOBR

SWKS

Why Pinterest Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket

Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cyclacel Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cycc-stock-quote/">CYCC</a>) just reported results for the first quarter of 2024.<ul><li>Cyclacel Pharmaceuticals reported earnings per share of -$2.27. This was above the analyst estimate for EPS of -$4.74.</li><li>The company reported revenue of $29,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/cycc-stock-earnings-cyclacel-pharmaceuticals-for-q1-of-2024/">CYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS for Q1 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cytokinetics (CYTK – Research Report), Perspective T...

Analysts Are Bullish on Top Healthcare Stocks: Cytokinetics (CYTK), Perspective Therapeutics (CATX)

Cyclacel Pharmaceuticals (CYCC) has shared an announcement. During Cyclacel Pharmaceuticals, Inc.'s 2024 virtual Annual Meeting, stockholders appro...

Cyclacel Pharmaceuticals Announces Key Corporate Decisions at 2024 Annual Meeting

Cyclacel Pharmaceuticals Q2 2024 Earnings Preview

Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cyclacel Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cycc-stock-quote/">CYCC</a>) just reported results for the second quarter of 2024.<ul><li>Cyclacel Pharmaceuticals reported earnings per share of -72 cents. This was above the analyst estimate for EPS of -$1.43.</li><li>The company reported revenue of $4,000.</li><li>This was 86.67% worse than the analyst estimate for revenue of $30,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cycc-stock-earnings-cyclacel-pharmaceuticals-for-q2-of-2024/">CYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abeona Therapeutics (ABEO – Research Report), Cycl...

Analysts Conflicted on These Healthcare Names: Abeona Therapeutics (ABEO), Cyclacel Pharmaceuticals (CYCC) and Cardinal Health (CAH)

Cyclacel Pharmaceuticals GAAP EPS of -$0.72

Cyclacel files an appeal to Nasdaq delisting letter

ABEO

CATX

CYTK

Press Releases

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib's Potential as a Precision Medicine for Cancer

Health Care

Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

Legal

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

Comments

Cyclacel Pharmaceuticals

Noticias

Últimas noticias sobre Cyclacel Pharmaceuticals (NASDAQ:CYCC) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL